Disclaimer

The system provides an estimate of in vivo efficacy of commonly used antiretroviral drug combinations based on user-defined information of HIV genotype (mandatory) and additional patient information (recommended). The engine is not intended as a replacement for standard of care but can be used by HIV specialists as an additional treatment decision support tool. Although analysis of a large data set of medical records has shown a good performance of the system, there is no warranty that its use will improve patient health. HIV care must rely on a solid knowledge of the complex host-virus interaction and proper consideration of patient status and commitment.

Database

The EuResist Integrated DataBase (EIDB) was set up to develop the EuResist prediction system. The EIDB is currently one of the largest data sets suitable for training genotype-centered treatment response models.

The EIDB is open for scientific studies under approval of the Scientific Board and following the Authorship Policy.

The EIDB includes information about patients, drug therapies, AIDS defining events, CD4 and viral load measurements and HIV genomic sequences. As of April 2014 it contains the following data:

Patients 66.254
Therapies 159.261
Viral Load data 754.270
CD4 counts 789.306
PR sequences 65.688
RT sequences 66.145
IN sequences 3.328
V3 sequences 2.155
GP41 sequences 560
GP120 sequences 2.228

The EIDB integrates biomedical information from the three founding national databases: the ARCA database (Italy), the AREVIR database (Germany), and data from Karolinska Institute (Sweden). The original data set is continuously updated with new data in order to improve the accuracy of the prediction system.

Following the EIDB setup, other centers’ data have also been uploaded:

Instituto de Higiene e Medicina Tropical (Portugal); irsiCaixa Foundation (Spain); the Rega Institute (Belgium); Laboratoire de Rétrovirologie of CRP-Santé (Luxembourg), data from the DUET study conducted by Tibotec, the National Referral Laboratory of Rwanda, Ivanovsky Institute of virology, Russia, Boheringer Ingelheim.

2014 update
ARCA patients 29965
  therapies 75524
  viral_load_isolates 334604
  cd4_isolates 387853
  PR sequences 30496
  RT sequences 30824
  IN sequences 1043
  V3 sequences 0
  GP41 sequences 434
  GP120 sequences 1662
Karasi-Rwanda patients 865
  therapies 672
  viral_load_isolates 487
  cd4_isolates 488
  PR sequences 627
  RT sequences 630
  IN sequences 0
  V3 sequences 0
  GP41 sequences 0
  GP120 sequences 0
KAROLINSKA patients 9393
  therapies 35502
  viral_load_isolates 185406
  cd4_isolates 209715
  PR sequences 6321
  RT sequences 6497
  IN sequences 62
  V3 sequences 0
  GP41 sequences 0
  GP120 sequences 9
AREVIR patients 11637
  therapies 21518
  viral_load_isolates 122036
  cd4_isolates 125055
  PR sequences 9207
  RT sequences 9205
  IN sequences 1136
  V3 sequences 1869
  GP41 sequences 0
  GP120 sequences 0
LUXEMBOURG patients 742
  therapies 2895
  viral_load_isolates 15765
  cd4_isolates 15262
  PR sequences 2263
  RT sequences 2262
  IN sequences 534
  V3 sequences 286
  GP41 sequences 36
  GP120 sequences 0
VIROLAB_IRSICAIXA patients 1003
  therapies 6559
  viral_load_isolates 13755
  cd4_isolates 13488
  PR sequences 1383
  RT sequences 1383
  IN sequences 0
  V3 sequences 0
  GP41 sequences 0
  GP120 sequences 0
VIROLAB_LEUVEN patients 1246
  therapies 3782
  viral_load_isolates 25589
  cd4_isolates 23620
  PR sequences 1486
  RT sequences 1444
  IN sequences 227
  V3 sequences 0
  GP41 sequences 90
  GP120 sequences 175
BI patients 1361
  therapies 1571
  viral_load_isolates 11192
  cd4_isolates 0
  PR sequences 1571
  RT sequences 1571
  IN sequences 0
  V3 sequences 0
  GP41 sequences 0
  GP120 sequences 0
LISBON patients 9398
  therapies 11038
  viral_load_isolates 44292
  cd4_isolates 13182
  PR sequences 11698
  RT sequences 11698
  IN sequences 323
  V3 sequences 0
  GP41 sequences 0
  GP120 sequences 382
TIBOTEC patients 200
  therapies 200
  viral_load_isolates 700
  cd4_isolates 199
  PR sequences 200
  RT sequences 200
  IN sequences 0
  V3 sequences 0
  GP41 sequences 0
  GP120 sequences 0
RUSSIA patients 444
  therapies 0
  viral_load_isolates 444
  cd4_isolates 444
  PR sequences 436
  RT sequences 431
  IN sequences 3
  V3 sequences 0
  GP41 sequences 0
  GP120 sequences 0

How to contribute to the data base

You can contribute your data to the EuResist initiative and have the possibility to query the whole data set for study proposals (upon request). In order to facilitate the entry of additional data providers, general rules for participation have been agreed upon as follows.

  1. Data provided by external contributors are provided solely for development of the treatment response models (i.e. the focus of the EuResist project); any other use is subject to information to and explicit approval by the contributing center;
  2. The task of integrating new data into the EIDB will be carried out by EuResist with the collaboration of the data provider, limited to providing information on database platform and schema and sending data via the method agreed upon. Integrating data ensures a quality control made by the EIDB administrator at the advantage of the contributing center;
  3. The co-authorship policy reserves one slot for each data provider in each scientific paper and congress presentation provided this is in-line with the journal editorial policy in terms of limitation in the number of authors or kind of work performed;
  4. Data contributed remain the property of the contributing center for ever. The data provider reserves the right to have its data permanently removed from EIDB at any moment without any need to justify this decision. Should this occur, the data are considered available only for pending papers explicitly agreed upon, i.e. being submitted for publication;
  5. Should EuResist end, each external dataset will be removed from the EIDB unless the contributing center explicitly requests that the data remain in the EIDB